A First Dilemma in Cardiovascular Medicine Adherence Versus Personalized Therapy by Fuster, Valentin
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 4 , N O . 1 0 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 7 . 9 3 6EDITOR’S PAGEFrom the Zena and Michael A
School of Medicine at Mount SA First Dilemma in
Cardiovascular Medicine
Adherence Versus Personalized TherapyValentin Fuster, MD, PHDA dherence to therapy refers to “the extent towhich patients follow a general strategy ofmedical instructions, this implying an active
patient participation about the timing, dosage, and
frequency of taking medications, as well as about
compliance with health-related behavior or lifestyle
modiﬁcation” (1). Thus, current practice is to advise
the same pharmacological therapy or lifestyle modiﬁ-
cation to a wide range of patients who are all pre-
sumed to resemble one another in terms of disease
entity or of risk factor lifestyle category. Conversely,
personalized or individualized therapy is the art and
science of “coupling established clinical–pathological
indices with state-of-the-art molecular proﬁling, to
create diagnostic and therapeutic strategies precisely
tailored to each patient’s requirements” (2). Thus, in
the ﬁeld of oncology, this targeting of unique thera-
pies has met with great successes for a variety of
cancers based on patients’ molecular proﬁles. As a
result, the promise of personalized medicine or
therapy has been excitedly embraced by the medical
community at large. However, this excitement is, at
present, meeting with much less enthusiasm in car-
diovascular medicine for several reasons, but mainly
because of medication nonadherence and failure to
modify patient behavior. In fact, recent data on the
rates of compliance with lifestyle modiﬁcation and
prescribed medication adherence are “alarming” (3).
More than 50% of patients, on average, decide to
abandon the prescribed treatment, and the objectives
to improve their habits (quit smoking, lose weight, or
engage in physical activity) are met by an equal or
lower adherence percentage.. Wiener Cardiovascular Institute, Icahn
inai, New York, New York.Although Brazilian author Paulo Coelho’s
sentiment—“you shouldn’t believe in promises”—may
be considered somewhat negative (4), it provides a
helpful reminder, especially for clinicians who should
remain rooted in science and fact, to not get too
swept up in the promise of new ideas. In cardiovas-
cular medicine, we are constantly evaluating new
targets to improve patient outcomes. These outcomes
must drive our research and practices, not the
promise of personalized medicine. For instance, to
address the disappointing risk factor control in clin-
ical practice, we evaluated data from 3 large-scale,
randomized trials that focused on optimal medical
therapy to determine if formalized attempts at risk
factor control within clinical trials are effective in
achieving guideline-driven treatment goals for dia-
betic patients with coronary artery disease (5).
Including 5,034 diabetic patients, we found that the
percentages of patients achieving the 1-year low-
density lipoprotein cholesterol targets compared
with baseline increased from 55% to 77% in the
COURAGE (Clinical Outcomes Utilizing Revasculari-
zation and Aggressive Drug Evaluation) trial, from
59% to 75% in the BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) trial, and
from 34% to 42% in the FREEDOM (Comparison of
Two Treatments for Multivessel Coronary Artery
Disease in Individuals With Diabetes) trial. Although
similar improved trends were seen for systolic blood
pressure, glycemic control, and smoking cessation,
only 18% of the COURAGE diabetes subgroup, 23% of
BARI 2D patients, and 8% of FREEDOM patients
met all 4 pre-speciﬁed treatment targets at 1 year of
follow-up. Thus, a signiﬁcant proportion of diabetic
patients with coronary artery disease fail to achieve
pre-speciﬁed targets for 4 major modiﬁable cardio-
vascular risk factors in clinical trials. Based on these
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1060results, we recommend “that fundamentally new
thinking is needed to explore approaches to achieve
optimal secondary prevention treatment goals” (5).
Similarly, in commenting on a failed study to
develop a molecular imaging strategy that can
monitor myocardial angiotensin-converting enzyme-1
up-regulation as a function of progressive heart fail-
ure, Yancy et al. (6) adeptly stated, “meaningful
research focused on increasing our precision in the
prescription of evidence-based medical therapies for
heart disease should continue. But personalized
medicine remains an unfulﬁlled hope.” These types of
results may account for why the majority of cardio-
vascular specialists are not yet incorporating person-
alized medicine into their clinical “thinking” and
therapeutic options (7). There are exceptions, such as
pulmonary arterial hypertension or unusual rhythm
disturbances, which may require speciﬁc individual-
ized therapies. However, a number of our highly
esteemed colleagues strongly advocate pursuing
personalized cardiovascular treatments, whereas we
strongly argue for pursuing better adherence to com-
mon therapies, perhaps the highest priority in car-
diovascular medicine today.
The pathway to improving patient outcomes may
not lie in the ﬁeld of targeting and personalized
therapies. Our task as cardiovascular specialists is farmore simple and, yet, far more complex. How can we
overcome the lack of medication adherence and life-
style modiﬁcation? As an example, research is start-
ing to show that the polypill may overcome some of
the adherence barriers in secondary prevention in
countries where it is approved. However, pushing the
envelope further, the real key to improving our pa-
tient outcomes may be truly personal, as we attempt
to speak to our patients about making better choices,
connect with them about the cultural or socioeco-
nomic barriers to better lifestyle habits, or convince
them how critically important it is for them to impart
these better decisions to their children. We, as car-
diovascular specialists, are uniquely positioned to
help inﬂuence our patients and their families in pos-
itive ways—and although these successes may be seen
as small, they have the potential to save lives one
person at a time. Thus, I am prepared for my next
Editor’s Page: “A Second Dilemma in Cardiovascular
Medicine: Personalized Medicine Versus Personal
Interaction with the Patient.”
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